GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (XSWX:GSK) » Definitions » Cyclically Adjusted PS Ratio

GSK (XSWX:GSK) Cyclically Adjusted PS Ratio : (As of May. 17, 2024)


View and export this data going back to 2007. Start your Free Trial

What is GSK Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


GSK Cyclically Adjusted PS Ratio Historical Data

The historical data trend for GSK's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted PS Ratio Chart

GSK Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.35 1.82 2.11 1.75 1.73

GSK Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.73 1.66 1.78 1.73 2.03

Competitive Comparison of GSK's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted PS Ratio falls into.



GSK Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

GSK's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, GSK's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.031/131.6000*131.6000
=2.031

Current CPI (Mar. 2024) = 131.6000.

GSK Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2.162 99.800 2.851
201409 2.214 100.000 2.914
201412 2.453 99.900 3.231
201503 2.117 99.600 2.797
201506 2.192 100.100 2.882
201509 2.342 100.200 3.076
201512 2.373 100.400 3.110
201603 2.225 100.400 2.916
201606 2.314 101.000 3.015
201609 2.459 101.500 3.188
201612 2.435 102.200 3.135
201703 2.320 102.700 2.973
201706 2.321 103.500 2.951
201709 2.549 104.300 3.216
201712 2.541 105.000 3.185
201803 2.417 105.100 3.026
201806 2.425 105.900 3.014
201809 2.575 106.600 3.179
201812 2.580 107.100 3.170
201903 2.536 107.000 3.119
201906 2.449 107.900 2.987
201909 2.872 108.400 3.487
201912 2.831 108.500 3.434
202003 2.693 108.600 3.263
202006 2.259 108.800 2.732
202009 2.541 109.200 3.062
202012 -0.297 109.400 -0.357
202103 2.374 109.700 2.848
202106 1.841 111.400 2.175
202109 2.072 112.400 2.426
202112 2.134 114.700 2.448
202203 2.172 116.500 2.454
202206 2.037 120.500 2.225
202209 2.111 122.300 2.272
202212 2.046 125.300 2.149
202303 1.907 126.800 1.979
202306 1.993 129.400 2.027
202309 2.215 130.100 2.241
202312 2.153 130.500 2.171
202403 2.031 131.600 2.031

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GSK  (XSWX:GSK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


GSK Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK (XSWX:GSK) Business Description

Industry
Address
980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS
In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GSK (XSWX:GSK) Headlines

From GuruFocus

GSK: Step-Changing for Growth

By Pavaki Capital 11-16-2022

Campbell & CO Investment Adviser LLC Buys 1, Sells 4 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-18-2023

Top 5 3rd Quarter Trades of Parallax Volatility Advisers, L.P.

By GuruFocus Research GuruFocus Editor 11-22-2022

Top 5 4th Quarter Trades of HealthInvest Partners AB

By GuruFocus Research GuruFocus Editor 02-18-2023